Representative Greg Landsman (D-Ohio) recently sold shares of Eli Lilly and Company NYSE: LLY. In a filing disclosed on December 12th, the Representative disclosed that they had sold between $15,001 and $50,000 in Eli Lilly and Company stock on November 8th. The trade occurred in the Representative's "ROCKEFELLER CAPITAL MANAGEMENT (1)" account.
Representative Greg Landsman also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Ameriprise Financial NYSE: AMP on 11/8/2024.
- Purchased $1,001 - $15,000 in shares of United Rentals NYSE: URI on 11/8/2024.
- Sold $15,001 - $50,000 in shares of Amazon.com NASDAQ: AMZN on 10/15/2024.
- Sold $15,001 - $50,000 in shares of Exxon Mobil NYSE: XOM on 10/15/2024.
- Sold $1,001 - $15,000 in shares of Pfizer NYSE: PFE on 10/15/2024.
- Sold $1,001 - $15,000 in shares of Cheniere Energy NYSE: LNG on 10/15/2024.
- Sold $15,001 - $50,000 in shares of Phillips 66 NYSE: PSX on 10/15/2024.
- Sold $15,001 - $50,000 in shares of Diamondback Energy NASDAQ: FANG on 10/15/2024.
- Sold $1,001 - $15,000 in shares of NextEra Energy NYSE: NEE on 10/15/2024.
- Sold $1,001 - $15,000 in shares of Linde NASDAQ: LIN on 10/15/2024.
Eli Lilly and Company Price Performance
Shares of Eli Lilly and Company stock traded up $6.77 during trading on Friday, reaching $789.12. 3,059,403 shares of the stock traded hands, compared to its average volume of 3,205,345. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The business has a fifty day simple moving average of $833.49 and a two-hundred day simple moving average of $871.09. The company has a market capitalization of $749.13 billion, a price-to-earnings ratio of 85.31, a P/E/G ratio of 3.02 and a beta of 0.41.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analysts' expectations of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business's quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 EPS. Sell-side analysts expect that Eli Lilly and Company will post 13.18 EPS for the current year.
Eli Lilly and Company Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.76%. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 56.22%.
Eli Lilly and Company declared that its board has approved a stock repurchase plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its shares are undervalued.
Insider Transactions at Eli Lilly and Company
In related news, CAO Donald A. Zakrowski sold 900 shares of the business's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.13% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on LLY shares. Morgan Stanley restated an "overweight" rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Barclays decreased their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating on the stock in a research report on Thursday, October 31st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, September 16th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an "overweight" rating in a report on Friday, September 13th. Finally, Bank of America reaffirmed a "buy" rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,002.22.
View Our Latest Stock Analysis on LLY
Institutional Investors Weigh In On Eli Lilly and Company
Several hedge funds have recently modified their holdings of the business. Peterson Financial Group Inc. bought a new stake in Eli Lilly and Company during the 3rd quarter valued at $27,000. MidAtlantic Capital Management Inc. purchased a new position in Eli Lilly and Company in the third quarter valued at about $30,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at about $36,000. Morton Brown Family Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company's stock valued at $41,000 after buying an additional 15 shares in the last quarter. Finally, Cedar Mountain Advisors LLC grew its position in shares of Eli Lilly and Company by 53.3% in the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company's stock worth $41,000 after buying an additional 16 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.
About Representative Landsman
Greg Landsman (Democratic Party) is a member of the U.S. House, representing Ohio's 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2025. Landsman is also a member of the Cincinnati City Council in Ohio. He assumed office on January 2, 2018. His current term ends on January 1, 2024. Landsman (Democratic Party) is running for re-election to the U.S. House to represent Ohio's 1st Congressional District. He declared candidacy for the 2024 election. Greg Landsman was born in Cincinnati, Ohio, and lives in Mt. Washington, Ohio. Landsman earned a B.A. in economics and political science from Ohio University and an M.A. in theological studies, religion, and public policy from Harvard University in 2004. His career experience includes working as the executive director of The Strive Partnership with the KnowledgeWorks Foundation and the director of the Ohio Governor's Office of Faith-Based and Community Initiatives.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
